Browse Articles
Discover research articles across all indexed journals
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies.
861 Background: This study aimed to characterize and compare the profiles of inflammatory and immune responses (IFN-γ, CX3CR1, iNOS, PD-L1, CTLA-4, CD163, FOXP3), monoamine oxidases (MAO-A and MAO-B), and the expression of HABP4 (hyaluronan-binding protein 4) and SERBP1 (Serpine1 mRNA-binding protein 1) in bladder tissue samples from patients with initial non-muscle-invasive bladder cancer (NMIBC), BCG-unresponsive NMIBC, and muscle-invasive bladder cancer (MIBC). Additionally, we aimed to provide an overview of the involvement of these factors and their signaling pathways in the tumor microenvironment (TME) of bladder cancer (BC). Methods: A total of 60 formalin-fixed, paraffin-embedded bladder cancer samples were obtained from patients diagnosed with BC at the Paulínia Municipal Hospital and São Vicente de Paulo Charity Hospital, Brazil. The samples were classified into three groups (n= 20 samples per group): Group 1 – initial NMIBC, Group 2 – BCG-unresponsive NMIBC, and Group 3 – MIBC. Immunohistochemical analysis was performed to evaluate the expression of target markers. Results: MAO-A immunoreactivity was significantly elevated (p<0.05) in Groups 1 and 2 compared to Group 3. In contrast, MAO-B expression was significantly higher (p<0.05) in Groups 2 and 3 compared to Group 1. These findings suggest that MAO-A serves as a potential biomarker for superficial disease, whereas MAO-B may be associated with disease progression. Elevated levels of CTLA-4 and PD-L1 were observed in Group 1 relative to Groups 2 and 3 (p<0.05), indicating that BCG treatment reduces their immunoreactivity in both BCG-unresponsive NMIBC and MIBC phenotypes, thereby modulating the TME. Additionally, immunoreactivities of CD163 and FOXP3 were significantly increased (p<0.05) in Group 2, followed by Group 3, implying that FOXP3 + regulatory T cells and CD163 + M2 macrophages contribute to BCG treatment failure and tumor progression. Conversely, IFN-γ, CX3CR1, and iNOS expression were significantly elevated (p<0.05) in Group 1, indicating that a heightened infiltration of CX3CR1 + cells and iNOS + M1 macrophages creates a cytotoxic microenvironment more responsive to immunotherapeutic interventions. This study represents the first report of HABP4 and SERBP1 immunoreactivities in BC. SERBP1 expression was significantly higher (p<0.05) in Groups 2 and 3, linking its overexpression to tumor progression. In contrast, HABP4 expression was significantly elevated (p<0.05) in Group 1 compared to Groups 2 and 3, supporting its role in inhibiting cell proliferation. Conclusions: These findings suggest that analyzing markers such as MAO-A, MAO-B, HABP4, and SERBP1 can improve risk stratification, prognosis, and personalized therapies for BC patients, particularly in the context of immunotherapies. Identifying specific profiles in the TME can guide more effective, tailored treatments and enhance clinical outcomes.
The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia.
556 Background: This study is to evaluate the safety and feasibility of local anesthesia (LA) for percutaneous ultrasound/computed tomography (US/CT)-guided bipolar radiofrequency ablation (RFA) for small renal masses (SRMs) by comparing the LA with general anesthesia. Methods: A retrospective review was carried out between 2018 to 2023, 212 patients with SRMs were treated with US/CT-guided bipolar RFA. General anesthesia (GA) was performed in 91 and LA was performed in 121 patients. Demographics, tumor characteristics, peri-procedural data, pathologic and follow-up outcomes were analyzed. The factors associated with pain were also identified. Results: There was no significant difference in demographics and tumor characteristics between the LA and GA group. Several statistically significant decrease were observed in terms of procedural time ( P <0.001), hospital stays ( P <0.001) and hospital costs ( P <0.001). The maximum perceived pain in LA group comprised 57.9% (70 of 121) mild, 42.1% (51 of 121) moderate. The anxiety in LA group comprised 62.0% (75 of 121) mild, 36.3% (44 of 121) moderate, 1.7% (2 of 121) severe. On multivariate analysis, tumor diameter was a significant predictor for pain in RFA procedure (OR 1.470, P <0.001). All patients were followed up for a median (range) of 36 (12-48) months. Local recurrence occurred in 15.7% (19 of 121) of the LA group and in 13.2% (12 of 91) in GA group ( P =1.000). Moreover, there was no significant difference in the difference between postoperative eGFR and preoperative eGFR when comparing the two groups. Conclusions: Percutaneous bipolar RFA of SRMs using CT and ultrasound guidance under LA can be an effective and tolerable method for patients who are unfit for surgery and provide satisfactory oncologic control.
CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer.
850 Background: Neoadjuvant therapy before radical cystectomy (RC) is the the standard treatment for muscle-invasive bladder cancer (MIBC). However, a significant number of patients do not respond to these therapies. Identifying biomarkers predictive of treatment response and developing novel therapeutic strategies are crucial to improving patient management and survival. This study aims to investigate non-invasive biomarkers that can predict response to neoadjuvant therapy in MIBC patients and explore their potential use in the design of new therapies. Methods: Immunophenotyping was performed on blood and bladder tissue samples from MIBC patients at pre-treatment (transurethral tumor resection (TUR); n=17; chemotherapy n=13 and immunotherapy n=4) and post-neoadjuvant treatment (RC, n=21; chemotherapy n=18 and immunotherapy n=3). Plasma soluble CD39 (sCD39) and adenosine levels were measured by ELISA and an enzymatic assay, respectively. Treatment response was evaluated at RC, and patients were classified as non responders (³ypT2³N1) or responders (<ypT2ypN0). Results: Non responder patients exhibited a significant higher percentage of CD39 + cells in circulating total and different maturation CD4 + T cells subsets, particularly at TUR, suggesting a potential role in treatment resistance. CD39 + CD4 + T cells showed elevated PD-1 expression, decreased levels of Granzyme-B and Perforin, and strong correlations with the regulatory T cell marker FoxP3 and the checkpoint inhibitor TIGIT. Intratumoral CD39 + CD4 + T cells were also more frequent in non responder patients, correlating positively with the expression of tumor checkpoint inhibitors TIGIT and ICOS and the regulatory marker FoxP3. In blood, CD39 + CD4 + T cell frequencies correlated with sCD39 levels, which in turn were associated with adenosine concentration in plasma. Conclusions: CD39 expression in CD4 + T cells and its plasma levels emerge as promising biomarkers for predicting response to neoadjuvant treatment in MIBC. Targeting CD39 may offer a novel therapeutic strategy to overcome treatment resistance, potentially improving outcomes in MIBC patients.
Type 1 diabetes incidence during COVID-19 pandemic has not been influenced by COVID-19 vaccination in northern Italy region, Lombardy
Objective To describe the trends of type 1 diabetes(T1D) incidence in 0–17-year-olds over the years 2020–2023, and the COVID-19 vaccination uptake in Lombardy region. Methods Data about children and adolescents aged 0–17 years who received a diagnosis of T1D from 2020 to 2023 were extracted from the public computerized registry of the healthcare system of the Lombardy Region (Italy). After calculating the annual T1D incidence, the incidence in 2020, prior to the availability of vaccination, was compared to subsequent years. A separate analysis was conducted for the 12–17 age group, the first to receive vaccination. Results One thousand two hundred seventy-three T1D onsets were recorded. The distribution of T1D showed no significant annual variation by sex (p-trend = 0.338), mean age (9 years, p = 0.537) and age distribution (p-trend = 0.563). T1D incidence [95% CI/100.000] did not significantly change comparing 2020 [18.94/100.000 (CI 16.88–21.18)] with 2021 [21.82/100.000 (CI 18.90–23.44)], 2022 [20.77/100.000 (CI 18.59–23.13)] and 2023 [19.68/100.000 (CI 16.61–20.94)]. No differences in incidence were observed in the 12–17 age group during 2021–2023 when COVID-19 vaccination was available when compared to 2020 (p-wald > 0.05). The COVID-19 vaccination coverage was lower in children with diabetes onset compared to the same-age general population (38 vs 42%). Conclusions The incidence of T1D in children remained stable during the COVID-19 pandemic, regardless of the uptake of the vaccination.
Lifespan in rodents with MYT1L heterozygous mutation
CLARIFY: Positron emission tomography using <sup>64</sup> Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy—A phase 3 diagnostic performance study.
TPS429 Background: Prostate cancer (PC) is the second most prevalent cancer in men globally. In men with newly diagnosed, high-risk disease, PC most often spreads to the pelvic lymph nodes (LNs) before becoming widely metastatic. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is strongly overexpressed in PC, making it an ideal target for imaging and therapy. 64 Cu-SAR-bisPSMA may offer several advantages over the currently approved PSMA positron emission tomography (PET) agents due to its bivalent structure (SAR-bisPSMA) and longer half-life of 64 Cu (12.7h vs. <2h for 18 F and 68 Ga). 64 Cu-SAR-bisPSMA has demonstrated higher tumor uptake (2-3x), prolonged retention and detection of additional PC lesions compared to approved PSMA agents. This Phase 3 diagnostic trial aims to establish the diagnostic performance of 64 Cu-SAR-bisPSMA PET to detect regional nodal metastases in men with high-risk PC. Methods: CLARIFY (NCT06056830) is a multi-center, single-arm, non-randomized, open-label Phase 3 diagnostic study of 64 Cu-SAR-bisPSMA. The target population is patients with untreated, histopathology-confirmed PC with high-risk features, who are proceeding to radical prostatectomy (RP) with pelvic lymph node dissection (PLND). The primary endpoint is to assess the sensitivity and specificity of 64 Cu-SAR-bisPSMA PET to detect pelvic nodal metastases. Secondary objectives include assessment of safety and determining the positive and negative predictive value of 64 Cu-SAR-bisPSMA PET. A total of 383 patients will be enrolled. Standard of care (SOC) imaging will be acquired at screening (e.g. computed tomography [CT], approved PSMA PET/CT). Eligible patients will receive a single administration of 64 Cu-SAR-bisPSMA (200 MBq) followed by a PET/CT scan on Day 1 (1-4h post-dose, same-day imaging) and on Day 2 (24±6h post-dose, next-day imaging). Patients will then proceed to RP with PLND. The specimens from surgery will be processed and analyzed locally to derive the Standard of Truth (SOT). The 64 Cu-SAR-bisPSMA PET/CT scans will be interpreted locally and by 3 independent, blinded, central readers. Each reader will assess the scans for the presence of abnormal 64 Cu-SAR-bisPSMA uptake in the pelvic LNs, prostate gland, extra-pelvic LNs, visceral/soft tissue and bone. The diagnostic performance of 64 Cu-SAR-bisPSMA will be based on the PET result on the respective day independently (Day 1 and 2) matched against the SOT. The study is open for recruitment in sites in the United States and in Australia. Clinical trial information: NCT06056830 .
Neoadjuvant darolutamide and relugolix combination preceding radical prostatectomy for high risk localized and locally advanced prostate cancer: A phase I/Ib trial.
TPS433 Background: Intensive androgen blockade with combination novel hormonal agent (NHA) + androgen deprivation therapy (ADT) appears promising as neoadjuvant therapy for high-risk localized prostate cancer (PCa) undergoing radical prostatectomy (RP). An all-oral regimen combining relugolix and darolutamide may be feasible, convenient, efficacious and exhibit no significant drug-drug interactions as neoadjuvant therapy for high-risk localized PCa and may convert patients who were initially inoperable to operable. Additionally, the rapid reversibility of castration will allow the reliable determination of post-operative PSA nadir to inform tailored adjuvant therapy. Moreover, given the convenience, this regimen may constitute an excellent backbone to develop additional combinations in future. Hence, a rationale may be made to evaluate the combination of relugolix and darolutamide as neoadjuvant therapy for 12 weeks preceding RP for high-risk localized/locally advanced PCa. Methods: This is a Phase I/Ib non-randomized, uncontrolled, open-label clinical trial evaluating the primary objective of safety and feasibility of combination darolutamide (600 mg PO BID) and relugolix (360 mg on day 1, then 120 mg PO once daily) for 12 weeks as neoadjuvant therapy preceding RP which is to be performed ≥48 hours after and within 2 weeks after completion of neoadjuvant therapy. Patients included in this study must be a candidate for RP with stage cT2-4, N0-1, high risk (defined as Gleason score (GS) ≥ 4 + 3 with ≥ 6 positive systematic biopsies (SB); GS ≥ 4 + 3 with ≥ 3 SB and prostate-specific antigen (PSA) ≥ 20 ng/mL; GS ≥ 9 in ≥ 1 SB or targeted biopsies (TB); or ≥ 2 SB or TB with continuous GS ≥ 8, each with ≥ 80% involvement), histologically or cytologically confirmed adenocarcinoma of the prostate. The Phase I component will accrue 10 patients. If ≥7 patients complete neoadjuvant combination therapy followed by RP with no severe therapy-related adverse events for up to 4 weeks following RP, the regimen is considered feasible and accrual of 20 additional patients continues in the Phase Ib expansion component of the trial to achieve a total of 30 patients. Secondary objectives include clinical response, pathologic complete response with comparison with control matched untreated group that underwent upfront RP, rate of achieving undetectable PSA nadir and testosterone recovery to normal within 8 weeks after RP and post-operative complications. Pharmacokinetic studies are performed in the Phase I component. Blood, tumor and urine are stored for future correlative studies. The trial was activated in October 2024. Clinical trial information: NCT06631521 .
Assessing the clinical impact of tumor volume on response to <sup>177</sup> Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
175 Background: 177 Lu-PSMA-617, a PSMA-directed radionuclide therapy, is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177 Lu-PSMA-617 in low volume (LV) and high volume (HV) mCRPC, classified using the CHAARTED criteria. Methods: We conducted a retrospective review of the Mayo Clinic Prostate Cancer Registry, including mCRPC patients treated with 177 Lu-PSMA-617 at Mayo Clinic Rochester, MN, from August 2017 to August 2024. Patients were categorized based on CHAARTED criteria, which define high-volume disease by the presence of visceral metastases and/or four or more bone metastases, with at least one outside the vertebral column and pelvis. PSA-response rate (PSA-RR), overall survival (OS), PSA-progression-free survival (PSA-PFS), and radiographic progression-free survival (rPFS) were analyzed using Kaplan-Meier curves with log-rank tests, as well as uni- and multivariate Cox regression. Results: Of the 264 patients treated with 177 Lu-PSMA-617, 83 were classified as LV (median follow-up: 17.1 months) and 177 as HV (median follow-up: 13.7 months). LV patients had lower serum PSA levels (P < 0.0001), higher hemoglobin levels (P < 0.0001), and a longer time from diagnosis to treatment initiation (10.3 years vs. 7.2 years, P = 0.04). In the HV group, 92% had bone metastases, 60% had lymph node involvement, 54% had both, and 35% had visceral metastases. In the LV group, 64% had bone metastases, 84% had lymph node involvement, 25% had both, and none had visceral metastases. Median OS was 14.4 months for HV patients and 17.6 months for LV patients (P < 0.0001). Median PSA-PFS was 11.4 months for HV patients and 13 months for LV patients. Median rPFS was 9.1 months for HV patients and 10.6 months for LV patients. PSA-RR significantly differed between groups (P < 0.0001). In the HV group, 20% achieved CR (PSA < 0.2 ng/mL), 29% had PR (PSA decreased by ≥50%), 16% experienced SD, and 35% had PD (PSA increased ≥25% from nadir). In contrast, the LV group had 51% achieving CR, 10% achieving PR, 18% with SD, and 11% with PD. Conclusions: Lower disease volume in mCRPC is strongly associated with improved outcomes following 177 Lu-PSMA-617 therapy. These findings suggest that tumor burden is a key predictor of response to PSMA radioligand therapy.
Correction: A peripheral subepithelial network for chemotactile processing in the predatory sea slug Pleurobranchaea californica
Circulating lncRNA HOTAIR is a biomarker for pediatric acute lymphoblastic leukemia and mediator of miR-326 exosomal export
Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.
133 Background: There is an ongoing debate on the use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) following radical prostatectomy (RP). While there have been conflicting results regarding oncological outcome, the effect of concomitant ADT on health-related quality of life (HRQOL) remains elusive. We aimed to assess the impact of adding ADT to postoperative RT on long-term HRQOL by providing PROM data from a large contemporary cohort of patients undergoing RT following RP with a systematic follow-up of up to 10 yrs. Methods: n=1124 patients who underwent RT after previous RP at a large tertiary care center between 2010 and 2021 were identified within a prospective institutional database. Patients with previous post-op ADT were excluded. Patients were stratified by concomitant ADT (no ADT n=682; ADT n=436). PROMs were prospectively assessed preoperatively, prior and post RT and at a maximum follow-up of up to 120mo, applying the validated EORTC QLQ-C30- and the prostate cancer-specific QLQ-PR25-questionnaires. Correlation analysis and multivariable regression models were used to estimate the impact of ADT with postoperative RT on HRQOL. Results: Median duration of ADT received within the ADT-cohort was 21mo. Prior RT, no significant difference in general HRQOL assessed by the global health status domain (GHS) was found between the ADT cohort (69.6) and the no ADT cohort (68.9; p=0.88). Post RT (65.1 vs. 69.9; p=0.038) and after median follow-up of 59 months (62.8 vs. 68.1; p<0.001) patients in the ADT cohort reported significantly worse general HRQOL. In multivariable regression analysis stratified by age, BMI, pT-stage, urinary continence and erectile functioning, concomitant ADT was confirmed as an independent predictor for worse general HRQOL (OR 0.68, 95% CI 0.47-0.96, p=0.03). Correlation analysis revealed a significant correlation between longer duration of ADT and worse long-term general HRQOL (p<0.001). In line, multivariable linear regression analysis revealed longer duration of ADT to independently predict worse general HRQOL (p=0.041) (Table). Conclusions: In patients with postoperative RT, concomitant ADT yields worse long-term general HRQOL. A longer duration of ADT furthermore leads to worse long-term general HRQOL. Those results support careful patient selection for ADT with postoperative RT after RP. Multivariable linear regression for HRQOL. Variable B [regression coefficient] Beta [standardized regression coefficient] SE [standard error] p value Duration of ADT -0.272 -0.191 0.132 0.041 Age -0.127 -0.043 0.294 0.667 BMI -0.588 -0.120 0.444 0.188 ICIQ-SF-Score 0.914 0.012 6.729 0.892 IIEF5-Score 0.661 0.165 0.403 0.103 R² 0.341 Adjusted R² 0.336
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024).
452 Background: Ethnic and racial disparities in oncology clinical trial participation remain a pressing challenge. Despite initiatives by the NCI and FDA since 2017 aimed at addressing these disparities, significant gaps persist in cancer treatment access and clinical trial involvement for minority populations. Notably, data on minority participation in clinical trials for FDA-approved renal cell carcinoma treatments during the post-COVID-19 era is limited. Methods: From 2020 to 2024, we analyzed data from 2,940 patients enrolled in five clinical trials (CheckMate 9ER, CLEAR, KEYNOTE 564, LITESPARK 005, TIVO-3) that resulted in FDA approval of new agents or indications for renal cell carcinoma. All trials were industry-sponsored. We assessed and tabulated the reporting of racial demographics within these trials, employing chi-square statistics and machine learning algorithms to compared participation rates among White, Black, Asian and Hispanic patients against SEER data on renal cell carcinoma incidence. Results: Among the five trials, three (KEYNOTE 564, LITESPARK-005, and TIVO-3) reported racial data, but only two (KEYNOTE 564 and LITESPARK-005) provided information beyond White participants, including Black and Asian populations. No data on Hispanic participation was reported. Our analysis revealed that in the three trails providing racial data, 88% of participants were White indicating statically significant overrepresentation (p<0.0001). In the two trials with broader racial data, Black participation was only 1.2% signifying substantial underrepresentation (p<0.0001), while Asian representation was 11.6% with no significant disparity observed (p=0.05). Conclusions: The underrepresentation of minority groups (particularly Blacks and Hispanics) in FDA-approved clinical trials for renal cell carcinoma remains a significant concern in the post-COVID-19 landscape. Addressing these disparities necessitated the implementation of policies that enhance data collection and standardize ethnic classification. Additionally, international collaborative trials should prioritize distinct data reporting for U.S. participants, utilizing NCI SEER nomenclature for consistency.
Prostate-specific antigen (PSA) response in Black patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus abiraterone acetate (ABI): A real-world comparison.
50 Background: Treatment for patients with mCSPC include androgen deprivation therapy (ADT) with the addition of androgen receptor pathway inhibitors (ARPIs). APA and ABI are two ARPIs approved for use with ADT in patients with mCSPC. However, there is limited information on the comparative effectiveness of ARPIs among Black patients. Deep PSA decline ≥90% (PSA90) following initiation of an ARPI is associated with delayed disease progression and improved survival outcomes. This study aimed to compare the proportion of Black patients with mCSPC with PSA90 response by 6 months after APA or ABI initiation. Methods: A retrospective analysis was conducted where Black patients were assigned to exclusive cohorts based on the first APA or ABI dispensation or pharmacy claim on or after 9/17/2019 (index date). Clinical data from US community urology practices (PPS Analytics) were linked with insurance claims data (Komodo; 1/1/2016-12/31/2023). Black patients with ≥12 months of pre-index clinical activity were required to have a diagnosis for metastasis in the absence of castration resistance. Patients were followed from the index date until the earliest of index ARPI discontinuation or switch, radiopharmaceutical initiation, or end of clinical activity/data availability. Pre-index characteristics were balanced between cohorts using inverse-probability of treatment weighting. PSA90 was defined as the earliest ≥90% decline in PSA relative to pre-index PSA. Weighted Kaplan-Meier analysis and a Cox proportional hazards model were used to compare the proportion of patients achieving PSA90 and time-to-PSA90 response. Results: A total of 363 Black patients were identified. The 236 APA and 127 ABI patients’ pre-index characteristics were balanced after weighting (Table). Mean on-treatment follow-up was 11.1 months (APA) and 9.4 months (ABI). The mean number of PSA tests were 4.0 (APA) and 5.3 (ABI). By 6 months post-index, PSA90 response was achieved by a significantly greater proportion of APA patients, as compared to ABI patients (65.4% vs 49.0%; hazard ratio: 1.66 [95% confidence interval: 1.18, 2.35], p=0.004). Median time-to-PSA90 response was 3.3 months for APA and 9.1 months for ABI. Conclusions: This real-world study of patients with mCSPC showed that a higher proportion of Black patients initiating APA, as compared to ABI, attained a PSA90 response within 6 months of treatment initiation, consistent with findings in the overall population. Selection of appropriate ARPIs may reduce health disparities among Black patients with mCSPC. Weighted pre-index characteristics. APA N=236 ABI N=127 Standardized difference (%) Mean age, years 70.1 69.2 9.5 Metastasis type (%) Nodal 59.5 62.6 6.3 Bone 59.2 54.7 9.1 Visceral 14.4 11.6 8.4 Prior use of ADT (%) 88.7 86.6 6.6 Mean PSA level, ng/mL 23.8 24.1 0.6
Removal of sulfate pollutant from different samples of a river water using nanozeolite technology, case study: Gamasiab River, Iran
Human activities significantly impact on river water quality as a crucial water source. A study in the Gamasiab River analyzed samples from 16 points at three time periods, assessing element concentrations. The most polluted station was identified using spectrophotometric testing and treated with natural and modified zeolite nanoparticles for purification. Various acid and base combinations modified the nanoparticles, optimizing their effectiveness as adsorbents through tests under different conditions. Utilizing the Design Expert model, theoretical adsorption values were determined based on pH and adsorbent-pollutant ratio. The modified samples demonstrated 77% efficiency with 0.2 molar nitric and sulfuric acid. Interaction studies showed how phosphate and nitrate ions affected sulfate adsorption. Optimal adsorption conditions were defined at pH = 9.6 and D/C = 17.01, achieving 86.5% pollutant adsorption. The Freundlich isotherm, with a coefficient of determination of 0.92, was chosen over the Langmuir isotherm (0.79) for its superior performance. Therefore, applying zeolite nanoparticles efficiently eliminated sulfate pollutants from surface water resources at the laboratory.
Berberine attenuates obesity-induced skeletal muscle atrophy via regulation of FUNDC1 in skeletal muscle of mice
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
404 Background: Previous studies on the correlation between leukocyte telomere length (LTL) and prostate cancer (PCa) have shown contradictory results. Our study aims to further explore the potential relationship between LTL and PCa. Methods: In this study, a total of 229,022 male individuals were enrolled from the UK Biobank to investigate this association . Both unadjusted and covariates-adjusted Cox proportional hazards regression models were employed. The primary outcome was defined as the diagnosis of incident prostate cancer using in-patient data and the death registry of the UKB cohort. To validate the reliability of the primary findings, secondary analyses, including Mendelian randomization (MR) were conducted. Results: The primary analysis demonstrated that longer LTL was substantially associated with higher risk of prostate cancer, with associations remaining robust after adjusting for potential covariates (HR: 1.444, 95% CI: 1.247-1.673, P < 0.001). Similar results were observed when LTL was analyzed as both a continuous and categorical variable, and the association were shown to be inversely U-shaped. At the genetic level, the association was further validated using MR across different prostate cancer databases, with results consistent with our primary analysis. Conclusions: Our findings offer compelling evidence that leukocyte telomere length is an important risk factor for prostate cancer. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between leukocyte telomere length (analyzed both as a continuous variable and by quartile categories) and prostate cancer risk in the UK Biobank study. Model I Model II Model III Cases N Median HR 95%CI HR 95%CI HR 95%CI 10693 198830 0.810 1.505 1.301-1.741 1.454 1.256-1.683 1.444 1.247- 1.673 <0.001 <0.001 <0.001 2761 49708 0.683 ref ref ref 2782 49707 0.773 1.088 1.032 -1.147 1.087 1.031 - 1.145 1.084 1.029-1.143 2607 49707 0.849 1.090 1.033-1.151 1.086 1.029-1.146 1.084 1.028-1.144 2543 49708 0.960 1.187 1.124-1.253 1.174 1.112- 1.240 1.170 1.108-1.236 <0.001 <0.001 <0.001 Model I adjust for age; Model II adjust for demographic variables (age; ethnic background) and socioeconomic variables (socioeconomic status; education); Model III adjust for demographic variables (age class; ethnic background) socioeconomic variables (socioeconomic status; education) and lifestyle variables (alcohol intake frequency; smoking history; body mass index; duration of walks; sleep duration; blood pressure).
Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.
417 Background: Intraductal carcinoma of the prostate (IDC) is an aggressive histological variant of prostate cancer, characterized by the presence of malignant cells within the prostatic ducts. Retrospective studies have shown IDC linked to higher tumor grades and odds of lymphatic metastasis and worse oncological outcomes. In patient derived xerograph models, IDC can persist after castration, with a subpopulation of castrate tolerant cells able to regenerate upon testosterone restoration. This suggests that IDC contributes to therapy resistance and highlights the need to understand molecular alterations of IDC. This study aims to evaluate genomic profiles of these tumors in the GUNS trial. Methods: From 9/2021 to 8/2024, GUNS enrolled 95 patients in Canada. Diagnostic biopsies underwent Tempus’ CLIA-certified 648-gene panel DNA sequencing. A total of 93 patients were evaluable for genomic alterations. Of those, 81 additionally had immunohistochemistry (IHC) staining for PTEN. All biopsy specimens were centrally reviewed by TvK. Associations between IDC and genomic alterations or PTEN IHC staining (positive vs. negative/heterogeneous) were assessed by Fisher’s exact test, and the false discovery rate (FDR) was controlled using the Benjamini-Hochberg method. Only genomic alterations annotated as biologically significant by Tempus were considered for analysis. Results: Of the 93 evaluable patients, 36 (39%) had IDC on biopsy. PTEN IHC status showed a significant association with IDC status, with negative or heterogeneous PTEN IHC staining being more prevalent among IDC-positive cases (p = 0.002; FDR q = 0.05). Specifically, PTEN IHC staining was negative/heterogeneous in 15/32 (47%) IDC-positive cases but only 7/49 (14%) IDC-negative cases. Genomic PTEN (22% vs. 7%) and TP53 (19% vs. 9%) alterations were also more common in IDC-positive cases than IDC-negative cases, although these trends were not statistically significant. Conversely, CDKN1B was exclusively altered in IDC-negative cases (0% vs. 9%), and BRCA2 alterations (germline or somatic) were also more frequent in IDC-negative cases (3% vs 11%), but these observations were also not statistically significant. Relatively low frequencies of genomic alterations were likely impediments to statistical significance, warranting larger sample sizes to assess these trends. Conclusions: Negative or heterogeneous PTEN IHC staining was more common in IDC-positive cases, consistent with the known association between PTEN loss and aggressive disease. PTEN IHC status, along with other genetic markers, may help to define subgroups within prostate cancer that differ in their underlying biology and response to neoadjuvant treatment. This highlights the importance of integrating molecular and histological data to better understand prostate cancer progression and to tailor therapeutic approaches.
Access to immune checkpoint inhibitors (ICI) in patients randomized to the control arm of ICI phase 3 trials in urothelial and renal cell cancers.
448 Background: We investigated access to ICIs in patients (pts) randomized to the control arm across positive phase 3 trials for renal cell carcinoma (RCC) and urothelial carcinoma (UC) with an ICI-based regimen. Methods: A search of clinicaltrials.gov was performed in October 2024 including, “renal cell carcinoma” OR “urothelial cancer”, “immune”, and “phase 3”, producing 64 results. These were limited to trials with an investigational arm containing ICI therapy and without an ICI in the control arm, no cross over in initial trial design, and demonstrated overall survival benefit in the adjuvant or metastatic setting (any line). Analysis included completed studies with minimum median follow-up of 12 months and the most recent published subsequent therapy data. Results: Final analysis included 8 international trials (n=6 RCC; n=4 UC, table). Two trials (CheckMate 025, KEYNOTE-045) were conducted before ICI were approved for advanced UC and RCC. For RCC (n=5,138 pts enrolled from 2014-2019) each trial tested a PD-1 inhibitor (pembrolizumab n=3; nivolumab n=3) alone or in conjunction with a tyrosine kinase inhibitor (axitinib n=1; cabozantinib n=1; lenvatinib n=1) or a CTLA-4 inhibitor (ipilimumab n=1). Control arm consisted of a non-ICI regimen (sunitinib n=4; everolimus n=1; placebo n=1). Approximately 57% of pts randomized to the control arm received subsequent therapy, 67% of which was an ICI. For UC (n=2,736 pts enrolled from 2015-2022) each trial tested a PD-(L)1 inhibitor (avelumab n=1; pembrolizumab n=2; nivolumab n=1) alone or in combination with enfortumab vedotin (n=1) or gemcitabine-cisplatin (n=1). Control arm consisted of chemotherapy (n=3) or best supportive care (n=1). Approximately 59% of pts randomized to the control arm received subsequent therapy, 75% of which was an ICI. Conclusions: Pts randomized to the control arm of phase 3 ICI trials in UC and RCC did not consistently receive ICIs upon progression. Understanding how access to subsequent therapies impacts overall survival, further research is warranted to identify possible causes, including availability of ICIs in different geographical regions, loss to follow-up, or clinical deterioration of pts. Cancer Renal Cell Carcinoma Urothelial Carcinoma Trial CheckMate 025 CheckMate 214 KEYNOTE-426 CheckMate 9ER CLEAR KEYNOTE-564 KEYNOTE-045 JAVELIN Bladder 100 EV-302 CheckMate 901 Median Follow-Up (months) 72.0 67.7 39.9 44.0 33.0 57.2 14.1 39.6 17.2 33.6 Pts on Control Arm (number) 411 546 429 328 357 498 272 350 444 304 Any Subsequent Systemic Therapy (number, %) 296, 72.0% 372, 67.6% 300, 69.9% 133, 40.5% 221, 61.9% 145, 29.1% 91, 33.5% 252, 72.0% 313, 70.5% 156, 51.3% Pts on Control Arm that Received ICIs as Subsequent Systemic Therapy (number, %) 107/296, 36.1% 227/372, 61.0% 240/300, 80.0% 121/133, 90.1% 188/221, 85.1% 101/148, 68.2% 35/91, 38.5% 186/252, 73.8% 260/313, 83.1% 126/156, 80.8%
Impact of parental education on number of under five children death per mother in Bangladesh
One of the leading challenges of social development is the reduction of children’s deaths under the age of five. The primary focus of this research is to study the potential impact of parental education on under five children death in Bangladesh utilizing a secondary dataset extracted from the Bangladesh Demographic and Health Survey (BDHS), 2017–18. The total count of deceased children within a family is a non-negative numerical variable. The mean number of under five children death per 100 mothers is found to be 20 with variance of around 27, which indicates the presence of overdispersion. As the response variable exhibits 84.2% zero counts, we have considered three regression models in this research; Poisson model, zero-inflated Poisson model, and zero-inflated negative binomial model. Finally, zero-inflated negative binomial model, exhibiting the lowest AIC value, indicates that both maternal and paternal education have significant protective impact on under five children death. Specifically, greater levels of formal education achieved by the parents are associated with a decreased rate of children death.